anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aim 1. To establish the validity of putative physiological SMA biomarkers in the immediate postnatal period. A longitudinal, natural history examination of physiological markers of muscle innervation will be performed in healthy and SMA infants. The first week of life is the ideal first time point, with visits occurring at scheduled visits up to the age two. Compound motor action potential (CMAP) amplitude and electrical impedance myography (EIM) will be examined and will be correlated with motor function. Each of these is associated with muscle innervation and provides information on the number and function of lower motor neurons in the spinal cord, the cellular target of SMA therapeutic interventions. This trial will establish the natural history of these putative SMA biomarkers as the disease evolves in affected infants. Moreover, our approach will allow for measurements in pre-symptomatic and early symptomatic subjects and determine their predictive value.

Aim 2. To establish the validity of putative molecular SMA biomarkers in the immediate postnatal period. Survival Motor Neuron (SMN2) copy number is a valid, predictive molecular SMA biomarker; however, it is fixed, and therefore not useful as a biomarker of clinical progression or response to therapy. SMN messenger Ribonucleic acid (mRNA) ( and protein expression is variable in different cell types and, in mice, naturally decreases with age postnatally. In this study, SMN expression levels will be measured longitudinally in SMA patients and controls. Additional putative molecular SMA markers that have been identified to correlate with motor function will be determined in an effort to distinguish between predictive markers that change prior to development of weakness and those that change as a consequence of weakness.
The cognitive training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours. For memory strategy training, strategies will be performed daily; this will take only a few minutes a day to accomplish.
BACKGROUND AND OBJECTIVES: The psychological problems of hemodialysis (HD) patients are prominent, and benefit finding (BF) have been proven beneficial to physical and mental health, fewer researchers explored BF in HD patients. The aim of this study was to investigate the current status of BF in patients with chronic kidney disease and to analyze the factors influencing it in order to provide a reference for subsequent interventions.
METHODS: A cross-sectional study was done on 246 HD patients by convenience sampling in the hemodialysis center of a 3 A hospital in Shanghai from March to September 2019. The measures include General Information Questionnaire, Benefit Finding Scale, Perceived Social Support Scale, General Self-efficacy Scale, and Simplified Coping Style scale.
RESULTS: The median (interquartile range, IQR) score of BF was 66 (IQR = 19) and it was lower compared with other chronic diseases. Significant differences in BF scores were found between different age groups, HD duration categories, and understanding degrees of HD. Taking BF as the dependent variable, the results of multiple linear regression analysis showed that age, duration of HD, family support, other support, positive coping, and self-efficacy entered the regression equation to explain 43.8% of the total variation. Social support played an indirect effect in the relationship between positive coping and BF, accounting for 54.1% of the total effect.
CONCLUSION: The BF of HD patients is worrisome and affected by many factors. Medical staff could pay attention to the positive psychology of HD patients, and construct individualized interventions according to the influencing factors to improve their BF level and achieve physical and mental health.
This disclosure recognizes the fact that the technology of making vesicles from lecithin and lecithin-like molecules, although well known and highly developed, is associated with problems of instability. It is known that vesicles coalesce, rupture and spill their contents long before the vesicle is used for its intended purpose. It has been discovered and disclosed herein that the deterioration of the vesicle delivery system is due in part to the rupture of the bipolar lipid vesicle membrane by the contents of the core volume or by an external agent. For example, the more detergent-like the properties of the pharmacological agent within the vesicle core volume, the more pronounced will be the attack on the vesicle wall interior. These events in turn will lead to vesicle membrane rupture. This disclosure sets forth the proper manufacturing techniques to achieve vesicle stability following the discovery and also discloses a large-scale experiment which fully establishes the function taking place microscopically in the true vesicle. The experiment designed to substantiate the discovery is one using visible sized dialysis bags to show that gelatinized pharmacological agents are capable of existing without disruption in the appropriate solutions. The dialysis bag could not be used in the administration of a pharmacological agent to a person but illustrates on a large-scale what takes place microscopically in the actual vesicle environment.
Dent disease type 1 is characterized by pathogenic CLCN5 gene variants and impaired receptor-mediated endocytosis in proximal tubules. However, mutation-related abnormalities in proximal tubules have not yet been described. Here, we present three patients with CLCN5 alterations and distinct morphological changes of the apical endocytic-lysosomal apparatus. The proximal tubular ultrastructure was investigated in kidney biopsy samples of three boys genotyped for non-nephrotic proteinuria. Controls: seven patients with nephrotic-range glomerular proteinuria. The genotyping findings revealed an already-known missense mutation in one patient and hitherto undescribed frameshift variants in two patients. Low-molecular-weight proteinuria, focal global glomerulosclerosis, proximal tubular changes, and tubular calcium deposits characterized each case. Three subsets of proximal tubular cells were observed: those without any abnormality, those with aplasia of apical endocytic-lysosomal apparatus and shrinkage of cells, and those with hypoplasia of apical endocytic apparatus, accumulation of proteinaceous substance in dysmorphic lysosomes, and dysmorphic mitochondria. The distribution of subsets varied from patient to patient. In one patient with a frameshift variant, an oxidative stress-like injury of proximal tubular cells and podocytes accompanied the above-mentioned alterations. Focal aplasia/hypoplasia of apical endocytic apparatus and subsequent changes in cytoplasmic organelles characterized proximal tubules in the CLCN5 pathogenic variants.
Process for the preparation of cenobamate. The present invention refers to a novel process for the synthesis of 1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl carbamate, the active principle of the drug cenobamate, marketed as Ontozry{reg} in Europe and Xcopri{reg} in the United States (of formula VII). Said process is represented in Scheme 1, which can be carried out in steps or sequentially in a single reaction step, without the need to isolate the intermediates. The process is characterized by the use of mechanochemistry as an energy source in the synthetic process and by regioselectively obtaining substituted tetrazoles in Nitrogen N2 of formula VIII. The described process is fast, respectful with the environment and profitable from the economic point of view. {PICTURE}  (Machine-translation by Google Translate, not legally binding)
Although aberrant activation of the KRAS and PI3K pathway alongside TP53 mutations account for frequent aberrations in human gastric cancers, neither the sequence nor the individual contributions of these mutations have been clarified. Here, we establish an allelic series of mice to afford conditional expression in the glandular epithelium of KrasG12D;Pik3caH1047R or Trp53R172H and/or ablation of Pten or Trp53. We find that KrasG12D;Pik3caH1047R is sufficient to induce adenomas and that lesions progress to carcinoma when also harboring Pten deletions. An additional challenge with either Trp53 loss- or gain-of-function alleles further accelerated tumor progression and triggered metastatic disease. While tumor-intrinsic STAT3 signaling in response to gp130 family cytokines remained as a gatekeeper for all stages of tumor development, metastatic progression required a mutant Trp53-induced interleukin (IL)-11 to IL-6 dependency switch. Consistent with the poorer survival of patients with high IL-6 expression, we identify IL-6/STAT3 signaling as a therapeutic vulnerability for TP53-mutant gastric cancer.
Disclosed is an encapsulated composition comprising at least one core-shell microcapsule. The at least one core-shell microcapsule comprises a core containing at least one perfume ingredient and a shell surrounding the core. The shell comprises a thermosetting resin formed by reaction of a polyfunctional amine comprising at least one amino group with at least one polyfunctional isocyanate. The shell further comprises a cationic polymer comprising quaternary ammonium groups. The shell further comprises a polymeric stabilizer comprising fully or partially dissociated carboxylic acid groups. The nominal molar ratio of the amino groups and the quaternary ammonium groups to the carboxylic acid groups is from 0.9 to 1.1, preferably from 0.95 to 1.08, more preferably from 1.00 to 1.06.
SafeEShare Patents Act 1990 INNOVATION PATENT Devices assemble data records, from private and/or possibly sensitive sources, of type or types that may be useful for sharing in varying degrees with other interests that the owner hopefully recognizes operate with interests different and possibly even in conflict with his/her own. Onus of recognition remains with the data producer but functionality classifying, controlling and identifying data elements via hierarchies rests with the party most benefitting from its control including device level switching. Sharing restrictions are implemented via blockchain. Re-combination of different items of depersonalized data requires the cooperation of the person producing the original data. Re-sharing by DataAgencies of depersonalized data is assumed to be an allowable commercial imperative managed external to the system. The data model on the DataAgency side includes structures for measurement quality management, hierarchical classifications and boundary control.
NEW MATERIAL:The benzothiazole derivative of formula I (R<1> and R<2> are H, lower alkyl, haloalkyl, or hydroxyalkyl; R<1> and R<2> may together with adjacent N atom form a 5-6-membered saturated heterocyclic group which may contain additional O or N atom; when said heterocyclic group is piperazine ring, it may have a substituent group such as alkyl, alkenyl, phenyl, etc. at the 4-position) and its salt. EXAMPLE:6-(1-Piperazinylcarbonyl)-2-benzothiazolone. USE:A cardiotonic agent and hypotensor. It increases the contraction of the cardiac muscle and the coronary blood flow rate, etc. PREPARATION:The compound of formula I can be produced e.g. by reacting the benzothiazole derivative of formula II with the amine of formula III or its amino-activated derivative.
1397060 1,4-Dithiino-[2,3-c]-pyrrole derivatives RHONE-POULENC SA 4 Dec 1973 [4 Dec 1972 19 Oct 1973] 56043/73 Heading C2C Novel compounds of Formula I in which A is a phenyl, pyridyl, pyridazinyl, 2-, 3- or 4-quinolyl or naphthyridinyl radical, each radical optionally being substituted by one or more of halogen, C 1-4  alkoxy, C 1-4  alkyl, CN and NO 2 , R is C 1-4  alkyl, C 2-4  alkenyl, C 1-4  hydroxyalkyl and n is 0 or 1, and acid addition salts thereof, are prepared (a) by reacting a compound of Formula II with a compound of Formula III in which Ar is phenyl or C 1-4  alkyl-phenyl, or (b) when n is 0, by reacting a compound of Formula VII with a compound of Formula V and, if desired, converting a resulting free base into an acid addition salt. Compounds V are prepared by reacting 5,6- dihydro-1,4-dithiine-2,3-dicarboxylic acid with an amine of formula H 2 N-A to produce an imide of Formula VI and partially reducing this to give the desired compound V.  Compounds III are prepared by reacting a compound V with a chloroformate of formula Cl-CO-O-Ar. 2-Amino-7-chloroquinoline is prepared by reacting 2,7-dichloroquinoline with ammonia. 1-Chlorocarbonyl-4-ethylpiperazine is prepared by reacting 1-ethylpiperzine with phosgene. 2-Amino-7-methozy-1,8-naphthyridine is prepared by reacting 2-acetylamino-7-chloro-1,8- naphthyridine with sodium methoxide in refluxing methanol. 2-Amino-5-methoxy-1,8- naphthyridine and 7-amino-2-methoxy-4-methyl- 1,8-naphthyridine are similarly prepared. 1-Methylpiperazine-1-oxide dihydrochloride is prepared by reacting anhydrous HCl with 1- methyl-4-(t.-butoxycarbonyl)-1-piperazine-1-oxide hydrochloride, itself prepared from 1-methylpiperzine via t-butyl (4-methylpiperazin-1-yl) carboxylate. Pharmaceutical compositions having anticonvulsant, tranquillising, decontracturant and hypnotic activity, for oral, parenteral or rectal administration, comprise a compound of Formula I, or a pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutical carrier or coating.
PROBLEM TO BE SOLVED: To obtain a liquid formulation excellent in stability and useful for drink formulations, etc. by containing a specific ratio of a thiamin and taurine and bringing the alcohol concentration in the formulation lower than a predetermined value. SOLUTION: In this thiamin-mixed liquid formulation, the blended amount of taurine is 300-10,000 pts.wt. based on 1 pt.wt. of a thiamin such as thiamin nitrate, thiamin hydrochloride, etc., taurine is blended in 3.0-15 W/V% of total amount of the liquid formulation, and an alcohol concentration in the liquid formulation is <=0.1 V/V%. It is preferable to add substantially no crude drug derived from animals in the liquid formulation and bring the pH of the formulation to 2.0-6.0.
This project will use a double-blind, placebo-controlled, within-subject design to examine mavoglurant effects on alcohol craving, drinking, and subjective responses. Non-treatment seeking, heavy drinkers with Alcohol Use Disorder (AUD) will undergo 2 lab sessions, which include a Cue Exposure (craving) Paradigm (CEP) and an Alcohol Drinking Paradigm (ADP), as well as 1-week and 1-month follow up appointments. Prior to the first lab session, participants will be randomized to receive either 200 mg of mavoglurant or placebo. For the second lab session, participants will receive the other condition, mavoglurant or placebo, that they did not receive in the first lab session. Each session will be separated by at least a 5-8 day washout period to allow for complete washout of mavoglurant. This is followed by 1-week and 1-month follow up appointments.
Audio-based classification techniques for body sounds have long been studied to aid in the diagnosis of respiratory diseases. While most research is centered on the use of coughs as the main acoustic biomarker, other body sounds also have the potential to detect respiratory diseases. Recent studies on the coronavirus disease 2019 (COVID-19) have suggested that breath and speech sounds, in addition to cough, correlate with the disease. Our study proposes fused audio instance and representation (FAIR) as a method for respiratory disease detection. FAIR relies on constructing a joint feature vector from various body sounds represented in waveform and spectrogram form. We conduct experiments on the use case of COVID-19 detection by combining waveform and spectrogram representation of body sounds. Our findings show that the use of self-attention to combine extracted features from cough, breath, and speech sounds leads to the best performance with an area under the receiver operating characteristic curve (AUC) score of 0.8658, a sensitivity of 0.8057, and a specificity of 0.7958. Compared to models trained solely on spectrograms or waveforms, the use of both representations results in an improved AUC score, demonstrating that combining spectrogram and waveform representation helps to enrich the extracted features and outperforms the models that use only one representation. While this study focuses on COVID-19, FAIR's flexibility allows it to combine various multi-modal and multi-instance features in many other diagnostic applications, potentially leading to more accurate diagnoses across a wider range of diseases.
Besides the intervention of the exercise group after the exercises will be applied to interferential current through the device. Will be positioned 4 electrodes (8x5 cm), two upper and two lower (forming a square) around the center of the knee.
Use of butorphanol in geriatric patients, patients with renal impairment, patients with hepatic impairment, and during labor requires extra caution (see below and the appropriate sections in PRECAUTIONS).

The usual recommended dose for initial nasal administration is 1 mg (1 spray in one nostril). If adequate pain relief is not achieved within 60 to 90 minutes, an additional 1-mg dose may be given.

The initial dose sequence outlined above may be repeated in 3 to 4 hours as required after the second dose of the sequence.

For the management of severe pain, an initial dose of 2 mg (1 spray in each nostril) may be used in patients who will be able to remain recumbent in the event drowsiness or dizziness occurs. In such patients additional doses should not be given for 3 to 4 hours. The incidence of adverse events is higher with an initial 2-mg dose (see Clinical Trials).

The initial dose sequence in elderly patients and patients with renal or hepatic impairment should be limited to 1 mg followed, if needed, by 1 mg in 90 to 120 minutes. The repeat dose sequence in these patients should be determined by the patient’s response rather than at fixed times but will generally be no less than at 6-hour intervals (see PRECAUTIONS).
The present invention comprises a method of treating a patient having trauma-induced immune suppression in order to enhance the ability of the patient's immune system to resist opportunistic infection. According to the method a therapeutically effective amount of a non-specific biological response modifier is administered to the patient. Preferably the biological response modifier comprises natural membrane vesicles and ribosomes, in a suspending buffer. Most preferably, the ribosomes and vesicles are both derived from the bacterium Serratia marcescens. The biological response modifier is characterized by absence of substantial toxicity along with product consistency, thus overcoming problems encountered with other immunomodulators. In addition the invention comprises use of a non-specific biological response modifier in the manufacture of a medicament for the treatment of trauma-induced immune suppression. Preferably the non-specific biological response modifier is comprised of natural membrane vesicles and ribosomes in a suspending buffer. Most preferably, the ribosomes and vesicles are both derived from the bacterium Serratia marcescens.
BACKGROUND: Lactational mastitis is a common painful and debilitating inflammation of breast tissue, generally treated conservatively or with pus puncture in case of breast abscess. However, treating mastitis in patients with implantable surgical material located in the affected breast region can be extremely challenging. We present an unusual case of lactational mastitis complicated by pacemaker pocket infection in a breastfeeding mother.
CASE PRESENTATION: A 35-year-old pacemaker-dependent female developed lactational mastitis seven weeks postpartum. Initially, the condition was treated conservatively with analgesics and antibiotics. After abscess formation, pus was aspirated using fine-needle aspiration technique. Four weeks after mastitis resolution, pacemaker pocket infection developed. According to current cardiovascular implantable electronic device infection treatment guidelines a complete surgical extraction of the entire electronic system, followed by targeted antibiotic treatment and reimplantation of a new device after infection resolution, was recommended. However, after thorough discussion with the young woman and her family and after detailed review of surgery-related risks, she declined a potentially high-risk surgical procedure. Thus, only the pulse generator was explanted; pacing leads positioned in the sub-pectoral pocket; new pacemaker implanted on the contralateral side and broad-spectrum antibiotic therapy continued for six weeks. After breastfeeding cessation, and with chronic fistula development at the primary pacemaker implantation site, the possibility of delayed surgical intervention including complete extraction of retained pacemaker leads was again thoroughly discussed with her. After thoughtful consideration the woman consented to the proposed treatment strategy. A surgical procedure including transvenous lead extraction through the primary implantation venous entry site, using hand-powered bidirectional rotational sheaths, was successfully performed, removing all retained leads through the left subclavian venous entry site, and leaving the fully functional and clinically uninfected pacemaker on the contralateral site intact.
CONCLUSION: Although patients' decisions for delayed extraction in a case of cardiovascular implantable electronic device infection should be discouraged by attending physicians and members of interdisciplinary teams, our case shows that a stepwise treatment strategy may be successful as a bailout clinical scenario in patients with specific requests, demands and / or clinical needs.
New-onset diabetes after transplantation was defined as a fasting plasma glucose (FPG) level ≥ 126 mg/dL (7 mmol/L) or symptoms of diabetes plus casual plasma glucose concentrations ≥200 mg/dL (11.1 mmol/L), confirmed by repeat testing on a different day. According to these criteria, 63 patients were diagnosed as NODAT between years 2007-2010 but after the exclusion criteria of our study 57 patients with and 102 patients without NODAT were included in the study.
A medical information service selection method based on a hybrid optimization algorithm. By the method, the multidimensional attribute of the medical information service is extracted, and a model meeting the user concurrency requirement and multi-granularity is established. Compared with the existing model, the model considers the transaction attribute of the medical information service and designs the probability-based adaptive priority. A multi-granularity recursive decomposition method is adopted to obtain a combination scheme. The method solves the problem of service selection by using a hybrid optimization algorithm, mainly designs a particle encoding mode, and fuses a particle swarm, a cross mutation operator with priority and a simulated annealing method to obtain the optimal service. The cross mutation operator with the priority can avoid solutions which do not meet the transaction attributes, the particle swarm algorithm can realize rapid global search, the simulated annealing method can avoid falling into a local optimal solution, different methods complement each other, and the optimal effect is obtained by making the best of the differences.
The children in the intervention group will receive BoNT injections in the medial gastrocnemius and/or the semitendinosus muscle(s). As part of the standard treatment approach of the CP Reference Centre of the University Hospitals Leuven, the injections are followed by a period of bilateral stretching casts if indicated (below the knee walking casts and removable knee extension casts when necessary) and all children will receive intensive physical therapy and application of ankle foot orthoses following BoNT injections. The follow-up period for the current study is 8-10 weeks. During this intensive physical therapy period post-BoNT, the children in the intervention group will work on individualized treatment goals, which will be defined based on the baseline measurements during a multidisciplinary discussion with the treating physician (that is scheduled prior to the BoNT injections).